Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : American Home Products AHP -- Ignore unavailable to you. Want to Upgrade?

To: MadMatt who wrote (110)	8/12/1998 3:26:00 PM
From: TheSlowLane	Read Replies (2) \| Respond to of 169

I very much doubt that Celebra (MTC's COX-2 inhibitor) was the ONLY reason for the merger. Several pharmas are remaking themselves into Life Sciences companies (Novartis, Dupont) and this is a good way for AHP to head that way as well. Particularly given MTC's acquisitions in the seed area. Besides Celebra, MTC has several promising developments in the pipeline. From the MTC side, I understand that historically their marketing has been weak, and AHP brings strength to the table in that area. Finally, MTC had the joint marketing agreement on Celebra with Pfizer in place prior to the merger. Not sure if AHP will be marketing Celebra also, but I'd have to believe that they will be. p.s. Other companies are working on COX-2 inhibitors but it is widely believed that Celebra will be on the shelves before the others by 6 months to a year. This will give them a substantial lead and all of the media focus and attention that will come along with being first to market.